Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
One of them is performing much better than the other this year.
Mindfully Curated
One of them is performing much better than the other this year.
Not all the “Magnificent Seven” stocks are strong buys right now.
Meta has gone from disaster not long ago to leading the AI transition.
Schwab U.S. Dividend Equity ETF is a great option for those seeking passive income.
Here’s where I put my own money, and how I’ve done with my investments.
This energy sector leader continues to reward shareholders.
The price targets could come down but don’t let that scare you.
Buffett’s team has become an active tech investor over the years.
Brookfield Infrastructure has done a fantastic job growing shareholder value.
Tariffs on Chinese EVs were supposed to provide relief, but how much will they really help?
ConocoPhillips’ dividend will look even better in a low interest rate environment.
The big news gets released on Oct. 10. Here’s what you should know so far.
Following the Federal Reserve’s 50 basis point cut to the fed funds rate, traders think the Fed is just getting started.
It’s hard to bet against this company right now.
NNN REIT has one of the longest dividend growth streaks in the REIT sector.
The stock is down big from its highs, and it has a lot to prove.
This Apple supplier could ride the coattails of the iPhone maker and deliver impressive stock upside.
You can boost your future financial security by wiping out the chance of various financial regrets.
These two companies are each worth under $4 billion, but they’re packed with potential.
Eli Lilly and Lululemon operate in very different industries, but both are on promising trajectories.